Myelofibrosis (MF) is a rare blood cancer that leads to scarring in the bone marrow, which prevents the normal production of blood cells. The condition is a primary subtype of myeloproliferative neoplasms (MPNs) and, in some cases, starts as another MPN. Risk factors for primary MF are unclear, although a history of polycythemia vera (PV) or essential thrombocythemia (ET) are risk factors for development of secondary MF. The disease is stratified as low, intermediate, or high risk using various International Prognostic Scoring System scales, and the prognosis depends on individual risk factors including age, comorbidities, and treatment response.

Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
View More
Patrick DalyMyelofibrosis | June 17, 2024
MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.
Patrick DalyMyelofibrosis | June 10, 2024
Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.
Patrick DalyMyelofibrosis | June 7, 2024
Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.
Leah SherwoodMyelofibrosis | May 22, 2024
Prefibrotic PMF is an MPN with distinct characteristics comprising histopathological, clinical, and biological parameters.
Prithviraj Bose, MDMyelofibrosis | May 2, 2024
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Melissa BadamoMyelofibrosis | April 30, 2024
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Melissa BadamoMyelofibrosis | April 30, 2024
Splenic irradiation before HSCT is associated with reduced spleen size and lower incidence of relapse in patients with MF.
Melissa BadamoMyelofibrosis | April 29, 2024
Sotatercept monotherapy, and combined with ruxolitinib, is a safe and effective treatment for patients with PMF and anemia.
Melissa BadamoMyelofibrosis | April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Blood Cancers Today Staff WritersMyelofibrosis | April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Prithviraj Bose, MDMyelofibrosis | February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
Patrick DalyMyelofibrosis | March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Melissa BadamoMyelofibrosis | February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Keightley AmenMyelofibrosis | February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Claire Harrison, MD, FRCP, FRCPathMyelofibrosis | February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
Leah SherwoodMyelofibrosis | March 4, 2024
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Michael Grunwald, MDMyeloproliferative Neoplasms | December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
Patrick DalyMyelofibrosis | March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Sangeetha Venugopal, MDMyelofibrosis | March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.
Haifa Kathrin Al-Ali, MDMyelofibrosis | March 4, 2024
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
Melissa BadamoMyelofibrosis | December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Nico Gagelmann, MDMyelofibrosis | March 4, 2024
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
Emily HayesMyelofibrosis | March 4, 2024
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Emily HayesMyelofibrosis | March 4, 2024
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Emily HayesMyelofibrosis | March 4, 2024
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Hemoglobin and platelets are correlated with OS, while mutations in ASXL1, EZH2, IDH1/2, U2AF1, and SRSF2 are not.
Blood Cancers Today Staff WritersMyeloproliferative Neoplasms | December 7, 2023
Bomedemstat is an oral lysine-specific demethylase-1 (LSD1) inhibitor clinically active in patients with MPNs.
Emily HayesMyelofibrosis | March 4, 2024
The model could be helpful in understanding fibrotic progression in JAK2V617F mutation–positive MPNs.
Patrick DalyMyelofibrosis | March 4, 2024
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Ruben Mesa, MD, discussed the results at the 65th ASH Annual Meeting and Exposition.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
The use of combination therapies including XPO1 inhibitor selinexor is a potentially effective therapeutic strategy in MF.
Patrick DalyMyelofibrosis | March 4, 2024
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Blood Cancers Today Staff WritersMyelofibrosis | March 4, 2024
Review more from the post-hoc time-dependent analysis of the phase III Simplify-1, Simplify-2, and MOMENTUM trials.
Melissa BadamoMyelofibrosis | November 30, 2023
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Melissa BadamoMyelofibrosis | December 1, 2023
The multicenter trial studied genetic mutations across three cohorts.
Melissa BadamoMyelofibrosis | March 28, 2024
Researchers also observed potential disease modification via rapid stabilization of platelets and stable hemoglobin levels.
Patrick DalyMyelofibrosis | November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.
Melissa BadamoMyelofibrosis | November 16, 2023
The trial is based on “compelling data” from arm III of the ongoing phase II MANIFEST study.
Melissa BadamoMyelofibrosis | October 13, 2023
82.5% of MF patients experienced rapid significant decreases in palpable spleen size after two months of ruxolitinib therapy.
Melissa BadamoMyelofibrosis | February 8, 2024
The median duration of therapy is around three years in patients with intermediate or high-risk MF.
Patrick DalyMyelofibrosis | October 12, 2023
The analysis included 346 patients with CALR-mutated MF who were transplanted in 123 centers between 2005 and 2019.
Sangeetha Venugopal, MDMyelofibrosis | February 8, 2024
Myelofibrosis Awareness Day is marked on September 20th each year.
Leah LawrenceMyelofibrosis | February 8, 2024
Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting.
Leah LawrenceMyelofibrosis | February 8, 2024
The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy.
Leah LawrenceMyelofibrosis | September 18, 2023
In PERSIST-2, treatment with pacritinib demonstrated a significant SVR benefit compared with the best available therapy, incl
Leah SherwoodMyelofibrosis | October 11, 2023
Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease.
Section Editor

Latest News

June 21, 2024